Results 1 to 10 of about 172,507 (213)

High coffee intake is associated with lower grade nonalcoholic fatty liver disease: the role of peripheral antioxidant activity

Annals of Hepatology, 2012
Background & aims. Some phytochemicals present in coffee have a potential antioxidant role which seems to protect the human body against cardiovascular diseases, liver disease and malignancies.
Ylse Gutiérrez-Grobe, Norberto Chávez-Tapia, Vicente Sánchez-Valle, Juan Gabriel Gavilanes-Espinar, Guadalupe Ponciano-Rodríguez, Misael Uribe, Nahum Méndez-Sánchez   +6 more
doaj   +2 more sources

AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease [PDF]

Hepatology, 2023
Mary E. Rinella, Brent A. Neuschwander‐Tetri, Mohammad Shadab Siddiqui, Manal F. Abdelmalek, Stephen H. Caldwell, Diana Barb, David E. Kleiner, Rohit Loomba   +7 more
openalex   +2 more sources

Pathological Connections between Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease

Kidney Diseases, 2022
Background: Nonalcoholic fatty liver disease and chronic kidney disease are major public health issues worldwide. The clinical burden of nonalcoholic fatty liver disease is not only confined to liver-related morbidity and mortality, but it also includes ...
Huixia Liu, Chun Zhang, Jing Xiong
doaj   +1 more source

Engineered Hydrogels for Organoid Models of Human Nonalcoholic Fatty Liver Disease. [PDF]

Adv Sci (Weinh)
Liu Y, Gilchrist AE, Johansson PK, Guan Y, Deras JD, Liu YC, Ceva S, Huang MS, Navarro RS, Enejder A, Peltz G, Heilshorn SC.   +11 more
europepmc   +3 more sources

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review

Hepatology, 2023
Background and Aims: NAFLD is a leading cause of liver-related morbidity and mortality. We assessed the global and regional prevalence, incidence, and mortality of NAFLD using an in-depth meta-analytic approach.
Z. Younossi, P. Golabi, James M. Paik, Austin Henry, Catherine Van Dongen, L. Henry   +5 more
semanticscholar   +1 more source

Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease

Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2022
Aim: present clinical guidelines, aimed at general practitioners, gastroenterologists, cardiologists, endocrinologists, comprise up-to-date methods of diagnosis and treatment of non-alcoholic fatty liver disease.Key points.
V. T. Ivashkin, M. V. Maevskaya, M. S. Zharkova, Yu. V. Kotovskaya, O. N. Tkacheva, E. A. Troshina, M. V. Shestakova, I. V. Maev, V. V. Breder, N. I. Gheivandova, V. L. Doshchitsin, E. N. Dudinskaya, E. V. Ershova, Kh. B. Kodzoeva, K. A. Komshilova, N. V. Korochanskaya, A. Yu. Mayorov, E. E. Mishina, M. Yu. Nadinskaya, I. G. Nikitin, N. V. Pogosova, A. I. Tarzimanova, M. Sh. Shamkhalova   +22 more
doaj   +1 more source

ANTIOXIDANTS AS POTENTIAL BIOMARKERS OF NONALCOHOLIC FATTY LIVER DISEASE STAGES

Байкальский медицинский журнал, 2023
Nonalcoholic fatty liver disease is a complex and multifactorial pathology associated with multiple epigenetic, genetic and environmental factors, and its pathogenesis is still not fully understood.
Sofya D. Kravchenko, Natalia M. Kozlova, Olesya V. Tirikova, Vera Il. Bakhtairova   +3 more
doaj   +1 more source

Treatments for NAFLD [PDF]

Farmacja Polska, 2021
Non-alcoholic fatty liver disease (NAFLD) is categorised into simple steatosis, termed nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH).
Katarzyna Juszczyńska
doaj   +1 more source

Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial

Nature Network Boston, 2023
Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved treatment. MAESTRO-NAFLD-1 was a 52-week randomized, double-blind, placebo-controlled phase 3 trial evaluating the safety of resmetirom in adults with nonalcoholic fatty ...
Stephen A. Harrison, R. Taub, Guy W. Neff, K. Lucas, D. Labriola, S. Moussa, N. Alkhouri, Mustafa R Bashir   +7 more
semanticscholar   +1 more source

Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses

Frontiers in Pharmacology, 2023
Background: Resveratrol, a polyphenol found in various plants, is known for its diverse bioactivities and has been explored in relation to nonalcoholic fatty liver disease (NAFLD). However, no high-quality evidence exists regarding its efficacy.Objective:
Xuan He, Yubing Li, Xinyu Deng, Xiaolin Xiao, Jinhao Zeng   +4 more
doaj   +1 more source